Raise the PB sales mix from 6% to 20%
First written in FY2017. 2 of 5 entries say "Restated". Latest entry: FY2018.
1 other company's latest entry also says "Softened".
- FY2018SoftenedAnnual report
「The sales mix of these PB products within the relevant segment's sales increased from 6% as of the end of the prior consolidated fiscal year to 10% as of the end of the current consolidated fiscal year.」
The annual report does not state the 20% target during the fiscal year that had been reported through the previous quarter; it reports only the actual increase from 6% to 10%. - FY2018-Q3RestatedAnnual report
「In particular, to expand the product range and offer lower prices, the company plans to strengthen sales of products from the CGC Group, of which it is a member in the food products sector, products from NID (Japan Drug Chain Association), of which it is a member in the non-food products sector, and private-label (PB) products, including those developed in-house. It plans to increase the sales mix of these PB products from 6% at the end of the prior consolidated fiscal year to 20% during the current consolidated fiscal year, and had increased it to approximately 10% as of the end of the third quarter of the current consolidated fiscal year.」
The company continues to target a 20% PB sales mix during the fiscal year, with the ratio at approximately 10% as of the end of the third quarter. - FY2018-Q2RestatedAnnual report
「In particular, to expand the product range and offer lower prices, the company plans to strengthen sales of products from the CGC Group, of which it is a member in the food products sector, products from NID (Japan Drug Chain Association), of which it is a member in the non-food products sector, and private-label (PB) products, including those developed in-house. It plans to increase the sales mix of these PB products from 6% at the end of the prior consolidated fiscal year to 20% during the current consolidated fiscal year, and had increased it to approximately 10% as of the end of the second quarter of the current consolidated fiscal year.」
The company states its target of a 20% PB sales mix during the fiscal year and progress of approximately 10% as of the quarter-end. No substantive progress from the previous quarter-end's 10% is indicated. - FY2018-Q1AdvancedAnnual report
「In particular, to expand the product range and offer lower prices, the company plans to strengthen sales of products from the CGC Group, of which it is a member in the food products sector, products from NID (Japan Drug Chain Association), of which it is a member in the non-food products sector, and private-label (PB) products, including those developed in-house. It plans to increase the sales mix of these PB products from 6% at the end of the prior consolidated fiscal year to 20% during the current consolidated fiscal year, and had increased it to 10% as of the end of the first quarter of the current consolidated fiscal year.」
The PB sales mix increased from 6% at the fiscal year-end to 10% at the end of the first quarter. The target of 20% during the fiscal year remains unchanged. - FY2017First statedAnnual report
「In particular, to expand the product range and offer lower prices, the company plans to strengthen sales of products from the CGC Group, of which it is a member in the food products sector, products from NID (Japan Drug Chain Association), of which it is a member in the non-food products sector, and private-label (PB) products, including those developed in-house. It plans to increase the sales mix of these PB products from the current 6% to 20% during the current fiscal year and will work to improve sales and the gross margin.」
The company has disclosed for the first time a numerical target to strengthen sales of PB products, including CGC Group, NID and in-house products, and increase the PB sales mix from the current 6% to 20% during the fiscal year.